Astria Therapeutics (NASDAQ:ATXS) Raised to "Strong-Buy" at Cantor Fitzgerald

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating in a report released on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Astria Therapeutics' FY2025 earnings at ($1.98) EPS.

Several other analysts have also commented on ATXS. HC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 11th. Citizens Jmp upgraded Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st. Wedbush reaffirmed an "outperform" rating and set a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Finally, JMP Securities initiated coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They issued an "outperform" rating and a $26.00 target price for the company. Five investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $30.00.

Astria Therapeutics Trading Down 2.0 %

ATXS traded down $0.11 during trading hours on Tuesday, hitting $5.26. The company's stock had a trading volume of 83,692 shares, compared to its average volume of 362,252. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $12.92. The business's 50-day moving average price is $5.40 and its 200-day moving average price is $7.85. The stock has a market cap of $296.56 million, a price-to-earnings ratio of -2.52 and a beta of 0.45.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.01. On average, analysts forecast that Astria Therapeutics will post -1.65 earnings per share for the current year.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ATXS. Fcpm Iii Services B.V. purchased a new position in shares of Astria Therapeutics during the fourth quarter worth about $25,680,000. Vestal Point Capital LP lifted its stake in Astria Therapeutics by 4.5% in the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company's stock valued at $37,369,000 after buying an additional 180,000 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Astria Therapeutics in the fourth quarter valued at approximately $707,000. Patient Square Capital LP grew its position in shares of Astria Therapeutics by 166.5% during the fourth quarter. Patient Square Capital LP now owns 105,057 shares of the biotechnology company's stock worth $939,000 after acquiring an additional 65,635 shares during the last quarter. Finally, Voya Investment Management LLC increased its holdings in shares of Astria Therapeutics by 367.4% in the 4th quarter. Voya Investment Management LLC now owns 71,708 shares of the biotechnology company's stock valued at $641,000 after acquiring an additional 56,366 shares during the period. Institutional investors and hedge funds own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.